Optical Preclinical Imaging - Global Strategic Business Report Forecasts Growth from $463M (2025) to $605.7M by 2032, Profiling Bruker, Fujifilm, PerkinElmer & TriFoil Imaging
Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Optical Preclinical Imaging - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.
The global optical preclinical imaging market was valued at US$463.0 million in 2025 and is projected to reach US$605.7 million by 2032, expanding at a compound annual growth rate (CAGR) of 3.9%. Market growth is supported by technological advances in fluorescence, bioluminescence and multimodal imaging, alongside rising investment in drug discovery, translational research and precision medicine.
Optical Preclinical Imaging Market Trends and Growth Drivers
Optical preclinical imaging has become integral to biomedical research by enabling non-invasive, real-time visualization of cellular and molecular processes in live animal models. Its application in longitudinal studies supports consistent data collection, reduces animal usage and improves experimental efficiency. These advantages are accelerating adoption across pharmaceutical and biotechnology companies, research institutes and academic laboratories.
In oncology research, optical imaging systems support the monitoring of tumor growth, metastasis, biomarker expression and therapeutic response. Applications are also expanding in immunology, neuroscience, infectious diseases and metabolic disorders. Researchers use optical imaging to evaluate immune-cell activity, pathogen-host interactions, neural function and disease progression, generating data that can support therapeutic discovery and validation.
Multimodal preclinical imaging is another important market trend. The integration of optical imaging with X-ray, computed tomography and magnetic resonance imaging combines functional and anatomical data, improving the accuracy and depth of preclinical analysis. These capabilities strengthen translational research and help connect preclinical findings with clinical development strategies.
Expanding Role in Drug Discovery and Precision Medicine
Pharmaceutical and biotechnology companies increasingly use optical preclinical imaging to assess drug efficacy, biodistribution, safety, dosing and target engagement. Real-time imaging data can improve candidate screening, support earlier identification of toxicity risks and streamline the selection of compounds for clinical development. The technology is particularly valuable for biologics, gene therapies, immunotherapies and other targeted treatments requiring precise monitoring.
The growth of precision medicine is further increasing demand for optical preclinical imaging systems. Detailed molecular and cellular analysis can support biomarker identification, patient-stratification research and the development of targeted therapies. In oncology and immunotherapy studies, optical imaging enables researchers to examine tumor biology, immune-cell behavior and treatment response within living models.
Gene-editing research also benefits from fluorescence-based monitoring of genetic modifications, cellular pathways and therapeutic effects. These applications are expanding the role of optical imaging in research involving complex diseases, rare disorders and personalised treatment strategies.
Market Segment and Regional Outlook
The report also examines market developments across Canada, Japan, Germany and the wider Asia-Pacific region, as well as Europe, Latin America, the Middle East and Africa.
Report Scope
The optical preclinical imaging market report provides an independent analysis of annual sales and forecasts from 2025 through 2032, presented in US$ million. Market segmentation includes bioluminescence/fluorescence imaging systems, standalone fluorescence imaging systems and optical systems integrated with X-ray or CT. End-use coverage includes pharmaceutical and biotechnology companies, research institutes and other users.
Geographic coverage encompasses the United States, Canada, Japan, China, Europe, Asia-Pacific, Latin America, the Middle East and Africa, with detailed analysis of major national and regional markets.
Key Report Benefits
Companies Featured
Featured companies include BioTek Instruments, Inc.; Bruker Corporation; Fujifilm Holdings America Corporation; Fujifilm Holdings Corporation; Magnetic Insight, Inc.; MBF Bioscience; Mediso Ltd.; MILabs B.V.; Miltenyi Biotec; MR Solutions; PerkinElmer, Inc.; TriFoil Imaging; UVP; and Vieworks Co., Ltd.
Domain Expert Insights
This market report incorporates perspectives from experts across enterprise, industry, academia and government. Insights are consolidated from multilingual multimedia sources, including text, voice and image-based content, to deliver comprehensive market intelligence and strategic analysis. As part of the research study, the report tracks and analyzes insights from 785 domain experts. Clients may request access to the expert network monitored for the report, together with the online expert insights tracker.
Key Attributes:
For more information about this report visit https://www.researchandmarkets.com/r/39awte
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.